Compare Solaris Energy Infrastructure Inc. Class A Common Stock (SEI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaris Energy Infrastructure Inc. Class A Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Solaris Energy Infrastructure Inc. Class A Common Stock trades at $68.5 (market cap $5.12B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Solaris Energy Infrastructure Inc. Class A Common Stock and Travere Therapeutics Inc. Common Stock are close in size by market cap, and Solaris Energy Infrastructure Inc. Class A Common Stock pays a 0.62% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Solaris Energy Infrastructure Inc. Class A Common Stock for 0 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SEI | TVTX | |
|---|---|---|
Market Cap | $5.12B | $4.88B |
Volume | 2,532,496 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $82.88 | $67.52 |
52-Week Low | $40.64 | $26.79 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.81B | $5.01B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SEI (Solaris Energy Infrastructure) trades at $77.83, down 1.83% today, but maintains strong analyst support with 9 unanimous buy ratings and a $100.56 consensus price target. The stock shows positive momentum with three consecutive quarterly earnings beats and projected revenue growth from $622M in 2025 to $762M in 2026. Recent technical analysis indicates neutral signals with support at $76 and resistance at $79.
The outlook remains positive given strong earnings performance and expansion initiatives, though elevated valuation ratios (P/E of 98.52) and significant debt issuance ($1.25B notes) present risks. The upcoming Q3 2026 earnings report on October 21 will be crucial for validating growth trajectory amid energy sector volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Solaris Energy Infrastructure Inc. Class A Common Stock
Solaris Energy Infrastructure, Inc. provides mobile power generation, control, and distribution equipment and logistics equipment for managing raw materials at well sites, operating through its Solaris Power Solutions and Solaris Logistics Solutions segments for data center, energy, commercial, and industrial customers.
Read more on SEI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
